Viewing Protocol Section

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
Viewing Protocol Section

Thank You for evaluating our software.

Clinical Trials

To give you an idea of how we make custom software. We have taken all of the Clinical Trials Information from our Federal Government(https://clinicaltrials.gov/).

The JSON File Structure of the files is as follows: Full Study -> Study => Sections => Modules. You are currently viewing a Protocol Section and its Modules.

We give the table structure here to give you an idea of what you are looking at. We put the explanation to the left and the data to the right.

A Protocol Section has the following Modules.

1. Identification Module

2. Status Module

3. Sponsor Collaborators Module

4. Oversight Module

5. Description Module

6. Conditions Module

7. Design Module

8. Arms Interventions Module

9. Outcomes Module

10. Eligibility Module

11. Contacts Locations Module

12. References Module

13. IPD Sharing Statement Module

Viewing Protocol Section

Study NCT06305754
Ignite Creation Date: 2024-05-06 @ 8:15 PM
Last Modification Date: 2024-10-26 @ 3:23 PM
Study NCT ID: NCT06305754
Protocol Section: NCT06305754
Start Identification Module Data
Expand Identification Module Data
Brief Title: Sacituzumab Tirumotecan MK-2870 Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor EGFR-Mutated Advanced Nonsquamous Non-small Cell Lung Cancer NSCLC and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors MK-2870-009
Official Title: A Randomized Open-label Phase 3 Study of MK-2870 vs Platinum Doublets in Participants With EGFR-mutated Advanced Nonsquamous Non-small Cell Lung Cancer NSCLC Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors
Acronym: None
Organization: Merck Sharp Dohme LLC
Organization Class: INDUSTRY
Organization Study ID: 2870-009
Secondary IDs
Secondary ID Type Domain Link
MK-2870-009 OTHER Merck None
2023-504910-31 REGISTRY None None
U1111-1288-3804 OTHER None None
Start Status Module Data
Status Verified Date: 2024-09
Overall Status: RECRUITING
Study First Submit Date:
Study First Submit QC Date:
Last Update Submit Date:
Status:
Start Sponsor Collaborators Module Data
Investigator:
Lead Sponsor: Merck Sharp Dohme LLC
Lead Sponsor Class: INDUSTRY
Lead Sponsor: Merck Sharp Dohme LLC
Start Oversight Module Data
Description Module:
Study Last Update Post Date Type(Status Module):
Attachment: Upload